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Abstract
Introduction: More new HIV-1 infections occur within stable HIV-1-discordant couples than in any other group in Africa, and
sexually transmitted infections (STIs) may increase transmission risk among discordant couples, accounting for a large
proportion of new HIV-1 infections. Understanding correlates of STIs among discordant couples will aid in optimizing
interventions to prevent HIV-1 transmission in these couples.
Methods: HIV-1-discordant couples in which HIV-1-infected partners were HSV-2-seropositive were tested for syphilis,
chlamydia, gonorrhea, and trichomoniasis, and HIV-1-uninfected partners were tested for HSV-2. We assessed
sociodemographic, behavioral, and biological correlates of a current STI.
Results: Of 416 couples enrolled, 16% were affected by a treatable STI, and among these both partners were infected in
17% of couples. A treatable STI was found in 46 (11%) females and 30 (7%) males. The most prevalent infections were
trichomoniasis (5.9%) and syphilis (2.6%). Participants were 5.9-fold more likely to have an STI if their partner had an STI
(P,0.01), and STIs were more common among those reporting any unprotected sex (OR=2.43; P,0.01) and those with low
education (OR=3.00; P,0.01). Among HIV-1-uninfected participants with an HSV-2-seropositive partner, females were
significantly more likely to be HSV-2-seropositive than males (78% versus 50%, P,0.01).
Conclusions: Treatable STIs were common among HIV-1-discordant couples and the majority of couples affected by an STI
were discordant for the STI, with relatively high HSV-2 discordance. Awareness of STI correlates and treatment of both
partners may reduce HIV-1 transmission.
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Introduction
While access to antiretroviral (ARV) medication will greatly
improve outcomes for people living with AIDS in sub-Saharan
Africa and may reduce transmission to susceptible partners [1,2],
these drugs alone may not stem the tide of new infections [3–5]. In
sub-Saharan Africa, an estimated 22.5 million people are living
with HIV-1 infection [6], the majority of whom are in stable
relationships [7]. In many areas with mature AIDS epidemics, up
to 15% of all couples are HIV-1-discordant and the majority of
new heterosexually acquired HIV-1 infections occur within such
discordant couples [8–11]. Interventions that appreciably reduce
the risk of transmission within HIV-1-discordant couples could
prevent a large proportion of all new infections [11], and therefore
these couples are an important population on which to focus
prevention efforts [12,13].
The presence of other sexually transmitted infections (STIs),
particularly ulcerative infections, is an important correlate of HIV-
1 transmission within discordant heterosexual couples [14–21].
While the risk of HIV-1 transmission within discordant couples is
relatively low during the chronic phase [13,22], periods of elevated
viral load and the presence of other STIs in one or both partners
are associated with significantly increased transmission risk
[14,17,23,24]. Because treatment of STIs often lowers genital
shedding of HIV-1 [19,25,26], timely diagnosis and treatment of
STIs, as part of a package of best prevention practices, may be an
important component in controlling the risk of HIV-1 transmis-
sion in discordant couples.
Three community interventions trials have investigated the
effect of enhanced STI treatment on the population-level
incidence of HIV-1 infection [27–29], only one of which found
a benefit associated with improved STI case management [27].
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design of the interventions, as well as differences in the stage of the
HIV-1 epidemics, background prevalence of STIs, and existing
STI treatment services [30]. There is more consistent evidence
that couple-level STI interventions that combine treatment and
behavioral counseling can reduce STI prevalence, risky sexual
behavior, and HIV-1 transmission [27,29,30].
Given the risk posed by the presence of an STI in either partner
in an HIV-1-discordant couple, addressing the couple as a unit
rather than as separate individuals may result in more effective
treatment of STIs and lower risk of HIV-1 transmission. We
examined the prevalence and correlates of STIs in a cohort of
Kenyan HIV-1-discordant couples and investigated the relation-
ship between the presence of an STI in one partner and the
likelihood of an STI in the other partner.
Methods
Study Participants
This study was conducted within a randomized clinical trial
testing the effectiveness of suppressive acyclovir therapy to prevent
HIV-1 transmission among stable HIV-1-discordant couples
where the HIV-1-infected participant was HSV-2-seropositive
(the Partners in Prevention HSV/HIV Transmission Study, which
operated at 14 African sites, including Nairobi) [8]. HIV-1-
discordant couples were recruited from voluntary counseling and
testing (VCT) centers and antenatal clinics in Nairobi, Kenya from
2004–2007. Eligible couples reported sex with each other $3
times in the 3 months prior to screening, planned to remain
together for the duration of the study, and were able to provide
independent informed consent for participation in the study. HIV-
1-infected participants were HSV-2-seropositive and had CD4
counts $250 cells/ml, did not have a history of clinical AIDS
(WHO stage IV), and were not currently on antiretroviral therapy
(ARV) or eligible for ARVs by Kenyan national guidelines.
At the enrollment visit, clinical staff administered a question-
naire including sociodemographic, sexual behavior, and medical
history characteristics. Included among these questions, partici-
pants were asked if they had been diagnosed with a genital
infection or if they had any genital sores in the 3 months prior to
enrollment. Participants were interviewed individually to ensure
confidentiality.
Identification of STIs and Laboratory Methods
At enrollment, all participants underwent a physical examina-
tion and specimens were collected to test for HIV-1, HSV-2,
syphilis, Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas
vaginalis, bacterial vaginosis (BV), and vaginal candidiasis. HIV-1
testing was by 2 different rapid tests conducted in parallel using a
combination of Uni-Gold Recombigen (Trinity Biotech plc,
Wicklow, Ireland), Determine HIV 1/2 (Abbott Laboratories,
Abbott Park, IL), and Vironostika HIV-1 Microelisa (bioMe ´rieux
Inc., Durham, NC), with confirmation by ELISA. Testing for
HSV-2 was by Focus ELISA (Cyprus, CA), using a cutoff of 3.5 to
improve specificity [31]. HIV-1-infected participants with inde-
terminate results (1.1–3.4) were eligible if confirmed by Western
Blot [32]. Testing for syphilis was by rapid plasma reagin (RPR)
test (Becton and Dickinson, Franklin Lakes, NJ) with confirmation
by T. pallidum haemagglutination assay (TPHA) (Randox Labora-
tories Ltd, Crumlin, UK). Testing for C. trachomatis, N. gonorrhoeae,
and T. vaginalis was conducted on urine samples for males and
cervical swabs for females. Testing for C. trachomatis and N.
gonorrhoeae was by the Gen-Probe Combo 2 assay following
manufacturer’s protocol (Gen-Probe, San Diego, CA). Testing
for T. vaginalis used TV analyte-specific reagents with APTIMA
General Purpose Reagents (Gen-Probe, San Diego, CA). TV
analyte-specific reagents include target capture, transcription-
mediated amplification (TMA), and hybridization protection,
using primers and probes that target TV rRNA [33]. Specimens
consistently yielding relative light unit (RLU) values .100,000
were considered positive. BV was defined by a Nugent score of 7–
10 on a Gram stain smear. Vaginal candidiasis testing was by wet
preparation. PAP smear slides were read using the Bethesda
system and findings of cervical intraepithelial neoplasia (CIN)
grade I or greater were classified as abnormal cervical cytology. All
participants with positive STI results or abnormal cytology were
treated per Kenyan national guidelines.
Statistical Methods
Prevalence of an STI was calculated for each etiology by
participant gender and HIV-1 status. Additionally, the prevalence
of any treatable STI (syphilis, gonorrhea, chlamydia, or tricho-
moniasis) was calculated. A couple was classified as affected by an
STI if one or both partners had an STI. In the event that STI
results were missing for one partner, the couple was classified as
affected if the other partner had an STI; however, if the other
partner was STI negative, couple STI status was classified as
unknown.
The prevalence of STIs was compared between HIV-1-infected
and uninfected participants, stratified by gender, using an odds
ratio (OR) with a p-value based on Fisher’s exact test. Individual-
level and couple-level characteristics were accessed as correlates of
a prevalent STI. Dichotomous characteristics were compared
between those with and without a current STI using a x2 test
(Fisher’s exact test was used for infrequent events), while
continuous and non-dichotomous categorical characteristics were
assessed using logistic regression. In assessing correlates of a
prevalent STI, adjustment for multiple comparisons was accom-
plished by controlling the false discovery rate at 5% and presenting
corrected p-values [34]. Tests for a difference in ORs between
groups were conducted by including an interaction term in a
logistic regression model. All analyses were conducted using
STATA statistical software (STATA Corp., College Station, TX).
Ethics Statement
Human experimentation guidelines of the US Department of
Health and Human Services were followed and approval for the
study, including forms for written informed consent, was obtained
from the Institutional Review Board of the University of
Washington and the Ethics and Research Committee of the
Kenyatta National Hospital. Written informed consent was obtain
from all study participants. The study was conducted following
Good Clinical Practice (GCP) and Good Clinical Laboratory
Practice (GCLP).
Results
Demographic Characteristics
A total of 416 HIV-1-discordant couples were enrolled, of which
322 (77.4%) couples had a female HIV-1-infected partner
(Table 1). The median relationship length was 5.2 years (IQR
2.5–10). Females (median age 30 years) were significantly younger
than males (median age 36 years; P,0.01, Wilcoxon rank-sum
test). Most (94.7%) couples reported that they were married.
Sexual Behavior
Median age at first sexual intercourse was 18 years among men
and 17 years among women, and women reported a median of 3
STIs in HIV-Discordant Couples
PLoS ONE | www.plosone.org 2 December 2009 | Volume 4 | Issue 12 | e8276lifetime sexual partners compared to 5 among men (P,0.01,
Wilcoxon rank-sum test). Couples reported a median of 4 sex acts
per month (IQR: 3–8), with no significant difference in the
number of acts reported by the male and female partners
(P=0.63, T-test). The majority of participants (79.1% of women
and 77.0% of men) reported no unprotected sex acts with their
study partner in the past month. Sex with someone other than the
study partner in the past month was reported by 4 (1.0%) women
and 5 (1.2%) men, and in all cases these participants were HIV-1-
infected.
Prevalence of Genital Infections in Participants
The most prevalent treatable STIs among all participants were
trichomoniasis and syphilis (Table 2). The prevalence of
trichomoniasis ranged from 2.1% to 8.5% with the highest
prevalence among HIV-1-infected females and the prevalence of
syphilis ranged from 1.9% to 3.2% with the highest prevalence
among HIV-1-uninfected females and HIV-1-infected males. A
treatable STI was identified in 46 (11.4%) women and 30 (7.2%)
men. Prevalence of a treatable STI was not different comparing
HIV-infected and uninfected participants, stratified by gender
(P.0.30). Bacterial vaginosis was common, with 24 (29.6%) HIV-
1-uninfected women and 89 (32.0%) HIV-1-infected women
testing positive for BV (OR=1.12; 95% CI 0.63–2.01; P=0.68).
Abnormal cervical cytology was observed in only 1 (1.2%) HIV-1-
uninfected woman compared to 17 (5.6%) HIV-1-infected women
(OR=4.97; 95% CI 0.75–210.06; P=0.14).
STI Concordance within Couples
A treatable STI was found in one or both partners in 65 of 403
(16.1%) couples. Of the 64 couples affected by a treatable STI
where the STI status was known for both partners, an STI was
identified in both partners in 11 (17.2%) couples, while in 35
(54.7%) couples only the female partner had an STI, and in 18
(28.1%) couples only the male had an STI (Figure 1).
HSV-2
By study design, all HIV-1-infected participants were HSV-2-
seropositive, while 234 (56.3%) HIV-1-uninfected participants
were HSV-2-seropositive. Among the HIV-1-uninfected partici-
pants 77.7% of women were HSV-2 seropositive compared to
50.0% of men (RR=1.55; 95% CI 1.33–1.81; P,0.01).
Seroprevalence of HSV-2 among the HIV-1-uninfected increased
with age among both females (OR=1.10 per year; 95% CI 1.02–
1.18; P=0.01) and males (OR=1.06 per year; 95% CI 1.03–1.09;
P,0.01). After controlling for age and gender, there was no
evidence of an association between HSV-2 seroprevalence and
relationship duration (OR=1.01; 95% CI 0.97–1.06; P=0.61) or
CD4 count of the HIV-1-infected partner (OR=0.96; 95% CI
0.89–1.04; P=0.37).
Correlates of STIs in Men and Women
Among the women, the presence of BV was strongly associated
with having a treatable STI (OR=3.68; 95% CI 1.76–7.79;
corrected P,0.01) (Table 3). While not significant after correcting
for multiple comparisons, there was a trend indicating that having
had genital sores within the past 3 months was associated with a
lower likelihood of having a treatable STI (OR=0.28; 95% CI
0.05–0.90; corrected P=0.15), with the association restricted to
HIV-1-infected participants (OR=0.17; 95% CI 0.02–0.69;
corrected P=0.03). Among males, we found no significant
associations with the presence of a treatable STI, after correcting
Table 1. Characteristics of study participants.*
Characteristic Female (N=416) Male (N=416)
Median (IQR
{) or Number (%)
Demographic
HIV-1 infected 322 (77.4) 94 (22.6)
Age 30 (26, 34) 36 (30, 41)
Married 395 (95.0) 396 (95.2)
Monthly income (US dollars)
{ 66.71 (40.03, 133.42) 93.40 (53.37, 200.13)
Education (years) 9 (7, 12) 11 (8, 13)
Employed 155 (37.7) 364 (88.6)
Reproductive History
Prior pregnancies 2 (2, 3) - -
Living children 2 (1, 3) 2 (1, 3)
Circumcised - - 345 (82.9)
Current oral contraceptive use 15 (3.6) - -
Sexual History
Age of first intercourse 18 (16, 19) 17 (15, 19)
Lifetime sexual partners 3 (2, 4) 5 (3, 10)
Any genital infection in past 3 months
1 72 (17.3) 30 (7.2)
Genital sores in past 3 months 80 (19.2) 61 (14.7)
Sex with someone else in past month 4 (1.0) 5 (1.2)
*Numbers may not add to total because of missing data.
{IQR, interquartile range.
{Based on conversion rate of 1 USD = 74.95 Kenyan Shillings.
1Includes urethritis, GUD, LGV, vaginitis, cervicitis, PID, syphilis, gonorrhea, chlamydia, trichomoniasis.
doi:10.1371/journal.pone.0008276.t001
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Female
HIV-1 (2) (N=94) HIV-1 (+) (N=322)
Characteristic N % n % OR 95% CI
Any treatable STI
{ 7 (8.1) 39 (12.3) 1.58 (0.67, 4.35)
Genital ulcer disease 1 (1.1) 5 (1.6) 1.39 (0.15, 66.38)
Syphilis 3 (3.2) 10 (3.1) 0.97 (0.24, 5.61)
Gonorrhea 0 (0.0) 0 (0.0) NA NA
Chlamydia 1 (1.2) 2 (0.6) 0.53 (0.03, 31.83)
Trichomoniasis 3 (3.5) 27 (8.5) 2.54 (0.75, 13.41)
Bacterial vaginosis 24 (29.6) 89 (32.0) 1.12 (0.63, 2.01)
Candidiasis 1 (1.2) 5 (1.6) 1.35 (0.15, 64.82)
Abnormal cervical cytology
{ 1 (1.2) 17 (5.6) 4.97 (0.75, 210.06)
Male
HIV-1 (2) (N=322) HIV-1(+) (N=94)
n % n % OR 95%CI
Any treatable STI
{ 25 (7.8) 5 (5.3) 0.67 (0.19, 1.84)
Genital ulcer disease 3 (0.9) 3 (3.2) 3.51 (0.46, 26.52)
Syphilis 6 (1.9) 3 (3.2) 1.74 (0.28, 8.31)
Gonorrhea 0 (0.0) 0 (0.0) NA NA
Chlamydia 4 (1.2) 0 (0.0) 0 (0.00, 3.28)
Trichomoniasis 16 (5.0) 2 (2.1) 0.47 (0.05, 1.82)
*Numbers may not add to total because of missing data.
{Positive laboratory result for syphilis, gonorrhea, chlamydia, or trichomoniasis.
{CIN 1 or greater.
doi:10.1371/journal.pone.0008276.t002
Figure 1. Concordance of treatable STIs identified in female and male partners. Slices of the pie represent the proportion of couples
affected and unaffected by an STI. The sections of the upper bar represent the proportion of affected couples in which both partners were infected
with an STI, only the female was infected, and only the male was infected.
doi:10.1371/journal.pone.0008276.g001
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between male circumcision and STI prevalence in men
(OR=3.08; 95% CI 0.74–27.21; corrected P.0.90) or women
(OR=1.10; 95% CI 0.46–3.06; corrected P.0.15).
Correlates of STI in the Couple
The presence of a treatable STI in one partner was strongly
associated with the likelihood of an STI in the other partner. A
participant was 5.9-fold more likely to have a treatable STI if their
partner also had an infection (OR=5.90; 95% CI 2.31–14.37;
corrected P,0.01). The likelihood of a treatable STI in the couple
decreased with the duration of the relationship (P,0.01, test for
trend) (Table 4). A treatable STI was more common in couples
that reported any unprotected sex in the past month (OR=2.43;
95% CI 1.34–4.37; corrected P,0.01) and in couples where one
or both partners had less than a primary school education
(OR=3.00; 95% CI 1.68–5.37; corrected P,0.01). While not
significant after correcting for multiple comparisons, there was a
trend indicating that a treatable STI was more common in couples
where at least one of the partners reported $1 outside sexual
partner in the past month (OR=4.36; 95% CI 1.23–15.49;
corrected P=0.09).
In couples that were discordant for the presence of a treatable
STI, the partner with the STI was the female partner in 35
(68.6%) of 51 couples, which was a significantly higher proportion
than would be expected by chance (P=0.01, binomial test). HIV-1
status was not associated with which partner in the couple had the
STI (RR=0.91; 95% CI 0.55–1.53; P.0.90). Among STI-
discordant couples the women were 4.5 years younger (95% CI
0.4–8.6 years) than couples where both partners had an STI. STI-
discordant couples did not differ from STI-concordant-positive
couples in terms of marital status, education, CD4 count,
relationship duration, male circumcision status, unprotected sex,
or outside sexual partners.
Table 3. Correlates of current sexually transmitted infection,* among female and male participants.
Characteristic Female Male
STI (2) (N=357) STI (+) (N=46) OR (95% CI) STI (2) (N=385) STI (+) (N=30) OR (95% CI)
n( % ) n( % ) n( % ) n( % )
Socio-demographic
Age $30 years 182 (51.7) 19 (41.3) 0.66 (0.33, 1.28) 296 (77.9) 23 (76.7) 0.93 (0.37, 2.66)
Home with 1 room 141 (40.1) 13 (28.3) 0.59 (0.28, 1.20) 156 (40.9) 9 (30.0) 0.62 (0.24, 1.45)
Employed 131 (37.2) 18 (39.1) 1.08 (0.54, 2.12) 338 (88.9) 25 (83.3) 0.62 (0.22, 2.19)
Behavioral
First sex ,15 years 27 (7.7) 7 (15.9) 2.26 (0.77, 5.79) 52 (13.7) 9 (30.0) 2.70 (1.03, 6.53)
Lifetime sex partners
1–3 121 (35.0) 11 (23.9) 1 (reference) 48 (12.6) 2 (6.7) 1 (reference)
4–6 178 (51.5) 25 (54.4) 1.54 (0.73, 3.26) 158 (41.5) 11 (36.7) 1.67 (0.36, 7.80)
$7 47 (13.6) 10 (21.7) 2.34 (0.93, 5.87) 175 (45.9) 17 (56.7) 2.33 (0.52, 10.44)
Unprotected sex acts
{
0 279 (80.2) 31 (68.9) 1 (reference) 294 (78.0) 19 (63.3) 1 (reference)
1–2 27 (7.8) 4 (8.9) 1.33 (0.44, 4.06) 34 (9.0) 4 (13.3) 1.82 (0.59, 5.66)
3–10 30 (8.6) 7 (15.6) 2.10 (0.85, 5.18) 37 (9.8) 5 (16.7) 2.09 (0.74, 5.93)
$11 12 (3.5) 3 (6.7) 2.25 (0.60, 8.41) 12 (3.2) 2 (6.7) 2.58 (0.54, 12.36)
Vaginal drying used 208 (58.3) 33 (71.7) 1.82 (0.89, 3.89) 231 (60.0) 17 (56.7) 0.87 (0.39, 2.01)
Biological
HSV-2-seropositive 61 (77.2) 6 (85.7) 1.77 (0.19, 85.89) 147 (49.7) 14 (56.0) 1.29 (0.52, 3.25)
History of STI 92 (25.9) 7 (15.2) 0.51 (0.19, 1.22) 181 (47.3) 13 (43.3) 0.85 (0.37, 1.93)
BV 88 (28.1) 23 (59.0) 3.68 (1.76, 7.79) –– –
Abnormal cervical cytology
{ 15 (4.4) 3 (7.3) 1.70 (0.30, 6.40) – – –
Any birth control 155 (43.4) 26 (56.5) 1.69 (0.87, 3.33) – – –
Oral contraceptives 12 (3.4) 3 (6.5) 2.01 (0.35, 7.83) – – –
Genital sores
" 72 (20.2) 3 (6.5) 0.28 (0.05, 0.90) 58 (15.1) 3 (10.0) 0.63 (0.12, 2.14)
Any genital infection
",1 56 (15.7) 6 (13.0) 0.81 (0.27, 2.04) 28 (7.3) 2 (6.7) 0.91 (0.10, 3.94)
Male circumcision 296 (83.1) 38 (84.4) 1.10 (0.46, 3.06) 314 (82.0) 28 (93.3) 3.08 (0.74, 27.21)
Partner with current STI 18 (5.1) 11 (23.9) 5.90 (2.31, 14.37) 35 (9.4) 11 (37.9) 5.90 (2.31, 14.37)
Bold indicates significant associations controlling the false discovery rate at 5% based on the Benjamini-Hochberg method.
*Positive laboratory result for syphilis, gonorrhea, chlamydia, or trichomoniasis.
{Unprotected sex acts with study partner in the past month.
{CIN 1 or greater.
"In the past 3 months.
1Includes urethritis, GUD, LGV, vaginitis, cervicitis, PID, syphilis, gonorrhea, chlamydia, trichomoniasis.
doi:10.1371/journal.pone.0008276.t003
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In this population of HIV-1-discordant couples in stable
relationships, we found that 12% of females and 7% of males
were infected with a treatable STI, with the highest prevalence
among the HIV-1-infected females. When considered as a couple,
approximately 1 out of every 6 couples was affected by a treatable
STI. The presence of an STI in an HIV-1-discordant couple may
pose increased risk of transmission of HIV-1 within the couple,
making diagnosis and treatment of STIs in these couples an
important component of reducing transmission. This study
indicates that treatable STIs may be common among HIV-1-
discordant couples, even if the relationships are considered stable.
The most common treatable STIs were trichomoniasis and
syphilis. Bacterial vaginosis was also common among both HIV-1-
infected and uninfected women, with 30–32% positive for BV.
Chlamydia was found in only 1% of participants, and gonorrhea
was not found in any of the participants. Among HIV-1-
discordant couples, identification of an STI in one partner is an
opportunity to counsel both partners about reducing their risk of
HIV-1 transmission. Treatment for ulcerative and non-ulcerative
infections is safe, effective, and cheap using readily available
medications, but re-infection from an untreated sexual partners is
common, making partner treatment important in STI manage-
ment [35,36].
As expected, the presence of a treatable STI was associated with
riskier sexual behavior (e.g., unprotected sex). Additionally, low
education was significantly associated with STI prevalence, a
finding that is consistent with previous studies [37–39]. Education
is likely a proxy for other socioeconomic factors affecting the risk
of acquiring an STI, but it may also be directly related to access to
condoms and knowledge about their importance and proper use.
The finding that among some participants the presence of genital
sores in the past 3 months was associated with lower likelihood of a
current treatable STI is initially counterintuitive. This association
is most likely due to recent syndromic STI treatment in response to
genital ulcers, resulting in decreased prevalence of treatable STIs.
Awareness of the risk factors and correlates of treatable STIs in
HIV-1-discordant couples can aid in the identification of an STI in
couples even if neither partner reports any symptoms.
While only 18% of couples affected by a treatable STI were
concordant for the infection, the presence of an STI in one partner
was highly associated with the likelihood of an STI in the other
partner. STI discordance could arise in a couple as a result of one
partner clearing the infection while the other remains infected or
in couples where the infection has not yet been transmitted within
the couple, or it could be an artifact of failure of the assay to detect
infection in one partner. In any case, STI discordance was
common, and is likely to lead to transmission of the STI to the
other partner if prevention and treatment measures are not
implemented. In this study, among the STI discordant couples, the
partner with the STI was more likely to be the female partner, but
no more or less likely to be the HIV-1-infected partner,
highlighting the importance of testing both partners in the couple.
Couple-focused voluntary counseling and testing programs can
be effective interventions to reduce HIV-1 transmission in couples
[40,41], achieved in part through increased rates of disclosure of
HIV status and increased condom use [42–46]. Negative
consequences of such programs have been minimal [47], although
disclosure can be associated with the break-up of some couples
[45]. While the emphasis of couple-focused programs has been on
disclosure and VCT, more work is needed to investigate the
benefit of ongoing couple-focused management of discordant
couples that extends past the disclosure stage. Prevention and
treatment of STIs would be a key component of such an approach.
The effectiveness of partner STI treatment is well established, but
conventional partner treatment programs may not take advantage
of the opportunity to provide additional counseling and risk-
reduction messages targeted specifically at discordant couples.
Despite the potential benefits, couple-focused STI management
programs must account for gender-specific needs as well as
prevention of negative consequences such as domestic violence.
Prevention of HSV-2 transmission may be another strategic
objective in discordant couples given the high proportion of
couples found to be HSV-2-serodiscordant. Among this popula-
tion of HIV-1-infected people who were also HSV-2-seropositive,
only 56% of their HIV-1-uninfected partners were also HSV-2-
seropositive. HIV-1-uninfected men in particular had a relatively
low HSV-2 seroprevalence (50%) compared to females (78%),
making the suppression of HSV-2 in their partners and the early
identification of HSV-2 outbreaks a potentially valuable interven-
tion [48]. Valacyclovir reduces transmission of HSV-2 [49], but
suppression of HSV-2 has not been demonstrated to reduce HIV-
1 transmission (Celum et al., in preparation) [50]. Previous studies
have shown that messages targeted at stable couples to prevent
STIs from outside partners are insufficient to prevent HSV-2
transmission, highlighting the importance of messages tailored to
HSV-2 prevention [51]. The relatively high rate of HSV-2
discordance particularly among male HIV-1 uninfected partners
provides a potential opportunity for intervention.
This study benefited from a relatively large sample size and was
nested within a clinical trial that provided a high level of quality
assurance. Nevertheless, some limitations exist. We used a
relatively high Focus ELISA cutoff of 3.5 to determine HSV-2
seropositivity, and therefore may have missed some true infections,
contributing to some of the HSV-2 serodiscordance. Detection of
syphilis is complicated by the difficulty of separating current
infections from historic treated infections. While the majority of
participants positive for syphilis had an RPR titer of at least 1:8,
Table 4. Couple characteristics associated with a couple
being affected by a current treatable sexually transmitted
infection.*
Characteristic
OR 95% CI
Married 0.36 (0.13, 1.10)
Less than primary education
{ 3.00 (1.68, 5.37)
CD4 count ,400 1.03 (0.56, 1.93)
Relationship duration
#1 1 reference
1–3 0.46 (0.19, 1.10)
$4 0.30 (0.14, 0.64)
Age difference (per 5 years) 0.93 (0.74, 1.16)
Female index partner 1.62 (0.77, 3.74)
Male circumcised 1.30 (0.59, 3.15)
Any unprotected sex in past month 2.43 (1.34, 4.37)
Other partners in past month 4.36 (1.23, 15.49)
Bold indicates significant associations controlling the false discovery rate at 5%
based on the Benjamini-Hochberg method.
*Positive laboratory result for syphilis, gonorrhea, chlamydia, or trichomoniasis
for either or both partners.
{For either or both partners.
doi:10.1371/journal.pone.0008276.t004
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represent past treated infections (data not shown). Finally, our
ability to generalize the findings of this study to discordant couples
in general is limited to some extent by the inclusion and exclusion
criteria of the randomized trial design. The study population is
likely to be somewhat healthier, due to the criteria of a CD4 count
$250 cells/ml, and more stable than couples in the general
population. This selection likely produced a study population with
less risky sexual behavior and fewer outside partners than the
general population, resulting in a lower prevalence of treatable
STIs. Additionally, by design, all HIV-1-infected participants were
HSV-2-seropositive; however, this is representative of the majority
of HIV-1-infected individuals in Africa [52].
This study provides useful information about the prevalence of
treatable STIs among HIV-1-discordant couples and the factors
associated with the presence of these infections. While the periods
of acute HIV-1 infection and late-stage disease pose the highest
per-contact risk of transmission, the intervening period of latent
infection is far longer, and is estimated to account for 44–51% of
heterosexual transmissions [53]. Therefore, understanding STIs
among discordant couples during latent infection is highly relevant
to HIV-1 prevention strategies. Approaches to STI management
among HIV-1-discordant couples that do not consider the
dynamics of such infections within couples may not fully address
their contribution to HIV-1 transmission. We have shown that
even among stable discordant couples, the prevalence of STIs and
genital infections is relatively high, and that STI discordance is
common. Therefore, approaching discordant couples as a unit
may improve the outcome of STI management, and facilitate
other risk reduction messages and interventions.
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